Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.

Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Tsubouchi H, Kumada H.

Hepatol Res. 2014 Oct;44(11):1047-55. doi: 10.1111/hepr.12221. Epub 2013 Sep 18.

PMID:
23941604
2.

Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B.

Ikeda K, Izumi N, Tanaka E, Yotsuyanagi H, Takahashi Y, Fukushima J, Kondo F, Fukusato T, Koike K, Hayashi N, Kumada H.

Hepatol Res. 2013 Jun;43(6):596-604. doi: 10.1111/j.1872-034X.2012.01115.x. Epub 2012 Nov 7.

PMID:
23131000
3.

Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data.

Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Tsubota A, Suzuki F, Arase Y, Murashima N, Chayama K, Kumada H.

Hepatol Res. 2000 Nov;18(3):252-266.

PMID:
11058829
4.

[The diagnostic value of serum hyaluronic acid, 7S domain of type IV collagen and AST/ALT ratio as markers of hepatic fibrosis in chronic hepatitis B and cirrhosis patients].

Park JH, Park CK, Kim ES, Park SY, Jo CM, Tak WY, Kweon YO, Kim SK, Choi YW.

Taehan Kan Hakhoe Chi. 2003 Jun;9(2):79-88. Korean.

PMID:
12824747
5.

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.

Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP.

Clin Chem. 2005 Oct;51(10):1867-73. Epub 2005 Jul 28.

6.

Efficacy of non-invasive elastometry on staging of hepatic fibrosis.

Saito H, Tada S, Nakamoto N, Kitamura K, Horikawa H, Kurita S, Saito Y, Iwai H, Ishii H.

Hepatol Res. 2004 Jun;29(2):97-103.

PMID:
15163431
7.

Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients.

Omran MM, Farid K, Emran TM, Attallah AA.

Arab J Gastroenterol. 2011 Jun;12(2):74-9. doi: 10.1016/j.ajg.2011.04.006. Epub 2011 May 17.

PMID:
21684477
8.

[Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease].

Kim SM, Sohn JH, Kim TY, Roh YW, Eun CS, Jeon YC, Han DS, Oh YH.

Korean J Hepatol. 2009 Dec;15(4):454-63. doi: 10.3350/kjhep.2009.15.4.454. Korean.

PMID:
20037264
9.
10.

Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.

Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Muga R.

J Viral Hepat. 2009 Jul;16(7):513-8. doi: 10.1111/j.1365-2893.2009.01103.x. Epub 2009 Feb 5.

PMID:
19200132
11.

Determination of serum fibrosis indexes in patients with chronic hepatitis and its significance.

Zheng M, Cai W, Weng H, Liu R.

Chin Med J (Engl). 2003 Mar;116(3):346-9.

PMID:
12781034
12.

Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C.

Zvibel I, Halfon P, Fishman S, Penaranda G, Leshno M, Or AB, Halpern Z, Oren R.

Liver Int. 2009 Feb;29(2):208-12. doi: 10.1111/j.1478-3231.2008.01830.x. Epub 2008 Aug 6.

PMID:
18694404
13.

The usefulness of measuring liver stiffness by transient elastography for assessing hepatic fibrosis in patients with various chronic liver diseases.

Tamano M, Kojima K, Akima T, Murohisa T, Hashimoto T, Uetake C, Sugaya T, Nakano M, Hiraishi H, Yoneda M.

Hepatogastroenterology. 2012 May;59(115):826-30. doi: 10.5754/hge11255.

PMID:
22469726
14.

Predicting the liver histology in chronic hepatitis C: how good is the clinician?

Romagnuolo J, Jhangri GS, Jewell LD, Bain VG.

Am J Gastroenterol. 2001 Nov;96(11):3165-74.

PMID:
11721766
15.

Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis.

Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, Murata M, Sawayama Y, Hayashi J.

Hepatol Res. 2007 Dec;37(12):1002-10. Epub 2007 Jul 1.

PMID:
17608672
16.

Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.

Coverdale SA, Samarasinghe DA, Lin R, Kench J, Byth K, Khan MH, Crewe E, Liddle C, George J, Farrell GC.

Am J Gastroenterol. 2003 Jun;98(6):1384-90.

PMID:
12818285
17.

Altered serum N-glycomics in chronic hepatitis B patients.

Gui HL, Gao CF, Wang H, Liu XE, Xie Q, Dewaele S, Wang L, Zhuang H, Contreras R, Libert C, Chen C.

Liver Int. 2010 Feb;30(2):259-67. doi: 10.1111/j.1478-3231.2009.02170.x. Epub 2009 Nov 27.

PMID:
19951379
18.

Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C.

Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E.

Ann Hepatol. 2009 Jan-Mar;8(1):26-31.

PMID:
19221530
19.

Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis.

Tatsumi C, Kudo M, Ueshima K, Kitai S, Ishikawa E, Yada N, Hagiwara S, Inoue T, Minami Y, Chung H, Maekawa K, Fujimoto K, Kato M, Tonomura A, Mitake T, Shiina T.

Intervirology. 2010;53(1):76-81. doi: 10.1159/000252789. Epub 2010 Jan 5.

PMID:
20068346
20.

Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients.

Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El-Dosoky I.

J Clin Lab Anal. 2013 Mar;27(2):121-9. doi: 10.1002/jcla.21572. Epub 2013 Mar 4.

PMID:
23460258

Supplemental Content

Support Center